GH

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 8

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust

Disclosed balance after: 48,235

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.80 to $66.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 7

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust

Disclosed balance after: 53,213

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 6

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust

Disclosed balance after: 62,235

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.80 to $64.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 5

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust

Disclosed balance after: 43,780

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.82 to $68.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 4

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust

Disclosed balance after: 45,341

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.80 to $67.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 3

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust

Disclosed balance after: 47,938

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.80 to $66.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 2

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust

Disclosed balance after: 53,375

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 1

Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust

Disclosed balance after: 61,031

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.80 to $64.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 6

Wiley Michael J · CIK 0001753789 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,358

F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.29 to $72.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 5

Wiley Michael J · CIK 0001753789 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,258

F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.24 to $72.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 4

Wiley Michael J · CIK 0001753789 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 353,960

F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.24 to $71.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 3

Wiley Michael J · CIK 0001753789 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,761

F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.24 to $70.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 2

Wiley Michael J · CIK 0001753789 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,061

F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.24 to $69.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 15

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,419

Underlying: COMMON STOCK · 6,916 shares

Expires 2028-08-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on August 22, 2018

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 14

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,214

Underlying: COMMON STOCK · 17,676 shares

Expires 2027-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error.

F10 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 1, 2017.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 13

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,679

Underlying: COMMON STOCK · 21,652 shares

Expires 2024-10-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The exercise price of $1.42 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error.

F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option on September 2, 2015, thereafter vests in equal monthly installments over 36 months.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 10

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,631

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share.

F6 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $72.92 to $73.86. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 9

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,479

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share.

F5 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $71.50 to $71.76. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 8

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 7

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,959

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 6

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,283

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-19-004540 · wf-form4_155571362598381.xml · derivative · entry 2

Jallal Bahija · CIK 0001730038 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,526

Underlying: COMMON STOCK · 4,526 shares

Expires 2029-04-16

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal annual installments over 3 years commencing on April 17, 2019.

SEC source: 0001628280-19-004540 · wf-form4_155571362598381.xml · nonDerivative · entry 1

Jallal Bahija · CIK 0001730038 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,837

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 12

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,331

Underlying: COMMON STOCK · 45,000 shares

Expires 2024-10-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The exercise price of $1.42 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error.

F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option on September 2, 2015, thereafter vests in equal monthly installments over 36 months.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 5

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,631

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share.

F4 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $76.44 to $76.64. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 4

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · derivative · entry 4

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,678

Underlying: COMMON STOCK · 9,145 shares

Expires 2027-11-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error.

F4 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017.

SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · derivative · entry 3

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,488

Underlying: COMMON STOCK · 72,627 shares

Expires 2027-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error.

F3 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017.

SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · nonDerivative · entry 2

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share.

SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · nonDerivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · derivative · entry 11

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,331

Underlying: COMMON STOCK · 45,000 shares

Expires 2024-10-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The exercise price of $1.42 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error.

F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option on September 2, 2015, thereafter vests in equal monthly installments over 36 months.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 3

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,631

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share.

F3 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $75.92 to $76.29. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 2

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,131

F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of one or more stock options at an exercise price of $1.43, $4.18 or $8.80 per share.

F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $73.86 to $74.19. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001628280-19-004409 · wf-form4_155554862858146.xml · nonDerivative · entry 1

Lanman Richard B. · CIK 0001721003 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-19-004054 · ownership.xml · nonDerivative · entry 2

SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner

SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,850,420

F2 · shares: This filing on Form 4 is being filed as a result of the transfer of 2,033,990 shares of Common Stock of the Issuer from SoftBank Group Capital Limited ("SBGC") to SoftBank Vision Fund (AIV M1) L.P., on or about March 12, 2019 in a private sale transaction. The transferred shares will remain subject to a lock-up agreement substantially the same as that certain Lock-Up Agreement dated June 28, 2018, by and among SBGC, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and the Issuer.

F1 · ownership.direct: The shares are directly held by SoftBank Vision Fund (AIV M1) L.P., or the Fund. SB Investment Advisers (UK) Limited, a wholly-owned subsidiary of SoftBank Group Corp., has been appointed as alternative investment fund manager, or AIFM, and is exclusively responsible for managing the Fund in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of the Fund, SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of the Fund's Investments. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001615774-19-004094 · ownership.xml · nonDerivative · entry 2

SOFTBANK VISION FUND (AIV M1) L.P. · CIK 0001755143 · 10% owner

SB INVESTMENT ADVISERS (UK) LTD · CIK 0001731509 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,850,460

F2 · shares: This filing on Form 4 is being filed as a result of the transfer of 2,033,990 shares of Common Stock of the Issuer from SoftBank Group Capital Limited ("SBGC") to SoftBank Vision Fund (AIV M1) L.P., on or about March 12, 2019 in a private sale transaction. The transferred shares will remain subject to a lock-up agreement substantially the same as that certain Lock-Up Agreement dated June 28, 2018, by and among SBGC, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and the Issuer.

F3 · balance_after: Due to a clerical error, the reporting person is filing this Amendment to Form 4 to correct the amount of non-derivative securities beneficially owned following the reported transaction from 27,850,420 (as reported on the original Form 4 filing) to 27,850,460.

F1 · ownership.direct: The shares are directly held by SoftBank Vision Fund (AIV M1) L.P., or the Fund. SB Investment Advisers (UK) Limited, a wholly-owned subsidiary of SoftBank Group Corp., has been appointed as alternative investment fund manager, or AIFM, and is exclusively responsible for managing the Fund in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of the Fund, SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of the Fund's Investments. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001628280-19-004558 · wf-form4_155596920454337.xml · nonDerivative · entry 1

Wiley Michael J · CIK 0001753789 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,358

F1 · shares: These shares represent shares that the reporting person donated as a gift to a donor advised fund administered by the Deseret Trust Company.

SEC source: 0001628280-19-000973 · wf-form5_154940483860384.xml · nonDerivative · entry 1

Wiley Michael J · CIK 0001753789 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 437,566

F1 · kind: Represents shares of Common Stock that the reporting person donated as a gift to a donor advised fund administered by the Deseret Trust Company.

SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · derivative · entry 4

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By TLS Beta Pte. Ltd.

Disclosed balance after: 0

Underlying: COMMON STOCK · 596,012 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · derivative · entry 3

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By TLS Beta Pte. Ltd.

Disclosed balance after: 0

Underlying: COMMON STOCK · 1,016,995 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · nonDerivative · entry 2

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By TLS Beta Pte. Ltd.

Disclosed balance after: 596,012

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

SEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · nonDerivative · entry 1

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By TLS Beta Pte. Ltd.

Disclosed balance after: 1,016,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

SEC source: 0001628280-18-012469 · wf-form4_153927861420408.xml · derivative · entry 4

Lightspeed Ultimate General Partner X, Ltd. · CIK 0001700549 · 10% owner

Lightspeed Affiliates X, L.P. · CIK 0001617751 · 10% owner

Lightspeed Venture Partners X, L.P. · CIK 0001602573 · 10% owner

Lightspeed General Partner X, L.P. · CIK 0001700550 · 10% owner

Eggers Barry · CIK 0001366048 · 10% owner

Liew Jeremy · CIK 0001700539 · 10% owner

Mhatre Ravi · CIK 0001366050 · 10% owner

Nieh Peter · CIK 0001366051 · 10% owner

SCHAEPE CHRISTOPHER J · CIK 0001185068 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Lightspeed Venture Partners X, L.P.

Disclosed balance after: 0

Underlying: COMMON STOCK · 1,169,163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F3 · ownership.nature: The shares are directly held by Lightspeed Venture Partners X, L.P. Lightspeed Ultimate General Partner X, Ltd. is the sole general partner of Lightspeed General Partner X, L.P., which is the sole general partner of Lightspeed Venture Partners X, L.P. Barry Eggers, Jeremy Liew, Ravi Mhatre, Peter Nieh and Christopher J. Schaepe are the directors of LUGP X and share voting and dispositive power with respect to the shares held by Lightspeed Venture Partners X, L.P. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001628280-18-012469 · wf-form4_153927861420408.xml · derivative · entry 3

Lightspeed Ultimate General Partner X, Ltd. · CIK 0001700549 · 10% owner

Lightspeed Affiliates X, L.P. · CIK 0001617751 · 10% owner

Lightspeed Venture Partners X, L.P. · CIK 0001602573 · 10% owner

Lightspeed General Partner X, L.P. · CIK 0001700550 · 10% owner

Eggers Barry · CIK 0001366048 · 10% owner

Liew Jeremy · CIK 0001700539 · 10% owner

Mhatre Ravi · CIK 0001366050 · 10% owner

Nieh Peter · CIK 0001366051 · 10% owner

SCHAEPE CHRISTOPHER J · CIK 0001185068 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Lightspeed Affiliates X, L.P.

Disclosed balance after: 0

Underlying: COMMON STOCK · 58,458 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.nature: The shares are directly held by Lightspeed Affiliates X, L.P. Lightspeed Ultimate General Partner X, Ltd. ("LUGP X") is the sole general partner of Lightspeed General Partner X, L.P., which is the sole general partner of Lightspeed Affiliates X, L.P. Barry Eggers, Jeremy Liew, Ravi Mhatre, Peter Nieh and Christopher J. Schaepe are the directors of LUGP X and share voting and dispositive power with respect to the shares held by Lightspeed Affiliates X. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001628280-18-012469 · wf-form4_153927861420408.xml · nonDerivative · entry 2

Lightspeed Ultimate General Partner X, Ltd. · CIK 0001700549 · 10% owner

Lightspeed Affiliates X, L.P. · CIK 0001617751 · 10% owner

Lightspeed Venture Partners X, L.P. · CIK 0001602573 · 10% owner

Lightspeed General Partner X, L.P. · CIK 0001700550 · 10% owner

Eggers Barry · CIK 0001366048 · 10% owner

Liew Jeremy · CIK 0001700539 · 10% owner

Mhatre Ravi · CIK 0001366050 · 10% owner

Nieh Peter · CIK 0001366051 · 10% owner

SCHAEPE CHRISTOPHER J · CIK 0001185068 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Lightspeed Venture Partners X, L.P.

Disclosed balance after: 1,169,163

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F3 · ownership.nature: The shares are directly held by Lightspeed Venture Partners X, L.P. Lightspeed Ultimate General Partner X, Ltd. is the sole general partner of Lightspeed General Partner X, L.P., which is the sole general partner of Lightspeed Venture Partners X, L.P. Barry Eggers, Jeremy Liew, Ravi Mhatre, Peter Nieh and Christopher J. Schaepe are the directors of LUGP X and share voting and dispositive power with respect to the shares held by Lightspeed Venture Partners X, L.P. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001628280-18-012469 · wf-form4_153927861420408.xml · nonDerivative · entry 1

Lightspeed Ultimate General Partner X, Ltd. · CIK 0001700549 · 10% owner

Lightspeed Affiliates X, L.P. · CIK 0001617751 · 10% owner

Lightspeed Venture Partners X, L.P. · CIK 0001602573 · 10% owner

Lightspeed General Partner X, L.P. · CIK 0001700550 · 10% owner

Eggers Barry · CIK 0001366048 · 10% owner

Liew Jeremy · CIK 0001700539 · 10% owner

Mhatre Ravi · CIK 0001366050 · 10% owner

Nieh Peter · CIK 0001366051 · 10% owner

SCHAEPE CHRISTOPHER J · CIK 0001185068 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Lightspeed Affiliates X, L.P.

Disclosed balance after: 58,458

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.nature: The shares are directly held by Lightspeed Affiliates X, L.P. Lightspeed Ultimate General Partner X, Ltd. ("LUGP X") is the sole general partner of Lightspeed General Partner X, L.P., which is the sole general partner of Lightspeed Affiliates X, L.P. Barry Eggers, Jeremy Liew, Ravi Mhatre, Peter Nieh and Christopher J. Schaepe are the directors of LUGP X and share voting and dispositive power with respect to the shares held by Lightspeed Affiliates X. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001628280-18-012505 · wf-form4_153930002073213.xml · derivative · entry 2

SoftBank Group Capital Ltd · CIK 0001755163 · 10% owner

SOFTBANK GROUP CORP · CIK 0001065521 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: COMMON STOCK · 2,033,990 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.direct: The shares are directly held by SoftBank Group Capital Limited, a wholly owned subsidiary of SoftBank Group Corp., a Japanese kabushiki kaisha. SoftBank Group Corp. may be deemed to have voting and dispositive power with respect to the shares held by SoftBank Group Capital Limited. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001628280-18-012505 · wf-form4_153930002073213.xml · nonDerivative · entry 1

SoftBank Group Capital Ltd · CIK 0001755163 · 10% owner

SOFTBANK GROUP CORP · CIK 0001065521 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,033,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2 · ownership.direct: The shares are directly held by SoftBank Group Capital Limited, a wholly owned subsidiary of SoftBank Group Corp., a Japanese kabushiki kaisha. SoftBank Group Corp. may be deemed to have voting and dispositive power with respect to the shares held by SoftBank Group Capital Limited. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0000947871-18-000817 · ownership.xml · derivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Royalties Opportunities II, LP

Disclosed balance after: 0

Underlying: Common Stock · 8,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series D Preferred Stock is convertible into Common Stock on a 0.7604-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series D Preferred Stock have no expiration date.

F2 · price: The Series E Preferred Stock is convertible into Common Stock on a 0.7378-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series E Preferred Stock have no expiration date.

F2 · derivative.exercise_date: The Series E Preferred Stock is convertible into Common Stock on a 0.7378-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series E Preferred Stock have no expiration date.

F2 · derivative.expiration_date: The Series E Preferred Stock is convertible into Common Stock on a 0.7378-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series E Preferred Stock have no expiration date.

F3 · ownership.nature: The shares are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and OrbiMed Advisors LLC ("Advisors") is sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. The Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0000947871-18-000817 · ownership.xml · derivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Royalties Opportunities II, LP

Disclosed balance after: 0

Underlying: Common Stock · 1,525,492 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series D Preferred Stock is convertible into Common Stock on a 0.7604-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series D Preferred Stock have no expiration date.

F1 · price: The Series D Preferred Stock is convertible into Common Stock on a 0.7604-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series D Preferred Stock have no expiration date.

F1 · derivative.exercise_date: The Series D Preferred Stock is convertible into Common Stock on a 0.7604-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series D Preferred Stock have no expiration date.

F1 · derivative.expiration_date: The Series D Preferred Stock is convertible into Common Stock on a 0.7604-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares of Series D Preferred Stock have no expiration date.

F3 · ownership.nature: The shares are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and OrbiMed Advisors LLC ("Advisors") is sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. The Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.